{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:28:34Z","timestamp":1772166514018,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007797","name":"University of Helsinki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03669-7","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:04:06Z","timestamp":1761905046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of tofacitinib treatment in Finnish patients with juvenile idiopathic arthritis: a real-life study"],"prefix":"10.1186","volume":"27","author":[{"given":"Tiina","family":"Lev\u00e4lampi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katariina","family":"Rebane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katriina","family":"Mikola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannu","family":"Kautiainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiina","family":"Aalto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"2","key":"3669_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J. ym. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"9563","key":"3669_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet"},{"key":"3669_CR3","doi-asserted-by":"crossref","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML. ym. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol Hoboken NJ. 2019;71(6):846\u201363.","DOI":"10.1002\/art.40884"},{"key":"3669_CR4","doi-asserted-by":"crossref","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST. ym. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res. 2022;74(4):521\u201337.","DOI":"10.1002\/acr.24853"},{"issue":"8","key":"3669_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/rheumatology\/kez048","volume":"58","author":"L Kearsley-Fleet","year":"2019","unstructured":"Kearsley-Fleet L, Vicente Gonz\u00e1lez L, Steinke D, Davies R, De Cock D, Baildam E. ym. Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. Rheumatology. 2019;58(8):1453\u20138.","journal-title":"Rheumatology"},{"issue":"8","key":"3669_CR6","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.3899\/jrheum.200437","volume":"48","author":"ML Mannion","year":"2021","unstructured":"Mannion ML, Xie F, Horton DB, Ringold S, Correll CK, Dennos A. ym. Biologic switching among nonsystemic juvenile idiopathic arthritis patients: A cohort study in the childhood arthritis and rheumatology research alliance registry. J Rheumatol. 2021;48(8):1322\u20139.","journal-title":"J Rheumatol"},{"issue":"4","key":"3669_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1136\/ard.2007.087130","volume":"68","author":"P Tynj\u00e4l\u00e4","year":"2009","unstructured":"Tynj\u00e4l\u00e4 P, V\u00e4h\u00e4salo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(4):552\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"3669_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144695","volume":"12","author":"I Melki","year":"2023","unstructured":"Melki I, Fr\u00e9mond ML. JAK inhibition in juvenile idiopathic arthritis (JIA): better understanding of a promising therapy for refractory cases. J Clin Med. 2023;12(14):4695.","journal-title":"J Clin Med"},{"issue":"2","key":"3669_CR9","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME. ym. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318\u201328.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"3669_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD. ym. Placebo-Controlled trial of Tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495\u2013507.","journal-title":"N Engl J Med"},{"issue":"3","key":"3669_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D Van Der Heijde","year":"2013","unstructured":"Van Der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C. ym. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve\u2010month data from a twenty\u2010four\u2013month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559\u201370.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3669_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253\u201361.","journal-title":"Ann Intern Med"},{"key":"3669_CR13","unstructured":"European Medicines Agency. Xeljanz. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf."},{"issue":"1","key":"3669_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-017-0212-y","volume":"15","author":"N Ruperto","year":"2017","unstructured":"Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, et al. Pharmacokinetic and safety profile of Tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J. 2017;15(1):86.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10315","key":"3669_CR15","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A. ym. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398(10315):1984\u201396.","journal-title":"Lancet"},{"key":"3669_CR16","doi-asserted-by":"crossref","unstructured":"Brunner HI, Akikusa JD, Al-Abadi E, Bohnsack JF, Boteanu AL, Chedeville G. ym. Safety and efficacy of Tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024;83(11):1561\u201371.","DOI":"10.1136\/ard-2023-225094"},{"issue":"12","key":"3669_CR17","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2012-202031","volume":"72","author":"F Mcerlane","year":"2013","unstructured":"Mcerlane F, Beresford MW, Baildam EM, Chieng SEA, Davidson JE, Foster HE. ym. Validity of a three-variable juvenile arthritis disease activity score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2013;72(12):1983\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3669_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/rheumatology\/kev353","volume":"55","author":"M Backstr\u00f6m","year":"2016","unstructured":"Backstr\u00f6m M, Tynj\u00e4l\u00e4 P, Ylijoki H, Aalto K, K\u00e4rki J, Pohjankoski H. ym. Finding specific 10-joint juvenile arthritis disease activity score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study. Rheumatology. 2016;55(4):615\u201323.","journal-title":"Rheumatology"},{"key":"3669_CR19","unstructured":"https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959."},{"key":"3669_CR20","doi-asserted-by":"publisher","first-page":"820586","DOI":"10.3389\/fped.2022.820586","volume":"10","author":"MM Kostik","year":"2022","unstructured":"Kostik MM, Raupov RK, Suspitsin EN, Isupova EA, Gaidar EV, Gabrusskaya TV. ym. The safety and efficacy of Tofacitinib in 24 cases of pediatric rheumatic diseases: single centre experience. Front Pediatr. 2022;10:820586.","journal-title":"Front Pediatr"},{"issue":"6","key":"3669_CR21","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/1756-185X.14324","volume":"25","author":"MM Rahman","year":"2022","unstructured":"Rahman MM, Laila K, Rahman SA. Efficacy and safety of Tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: a study from Bangladesh. Int J Rheum Dis. 2022;25(6):678\u201384.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"3669_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312174","volume":"20","author":"K Iman","year":"2025","unstructured":"Iman K, Akter L, Rahman MM, Laila K, Islam MI, Rahman SA. Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: extended experience from Bangladesh. PLoS ONE. 2025;20(1):e0312174.","journal-title":"PLoS ONE"},{"key":"3669_CR23","doi-asserted-by":"crossref","unstructured":"Consolaro A, Ruperto N, Lovell DJ, Synoverska O, Abud-Mendoza C, Spindler A. ym. Clinically inactive disease and remission in patients with juvenile idiopathic arthritis receiving tofacitinib: post hoc analysis of a phase III trial. J Rheumatol. 2025;52(9):919\u201326.","DOI":"10.3899\/jrheum.2024-0536"},{"key":"3669_CR24","unstructured":"https:\/\/www.kela.fi\/laake291."},{"issue":"9","key":"3669_CR25","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1093\/rheumatology\/keaa858","volume":"60","author":"J Fitton","year":"2021","unstructured":"Fitton J, Melville AR, Emery P, Nam JL, Buch MH. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. Rheumatology. 2021;60(9):4048\u201354.","journal-title":"Rheumatology"},{"key":"3669_CR26","doi-asserted-by":"crossref","unstructured":"Chighizola CB, Pellico MR, Pandolfi M, Marelli L, Cornalba M, Pontikaki I et al. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience. Clin Exp Rheumatol. 2023; https:\/\/www.clinexprheumatol.org\/abstract.asp?a=20066.","DOI":"10.55563\/clinexprheumatol\/4yoas8"},{"issue":"1","key":"3669_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K. ym. Safety and efficacy of Tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"3669_CR28","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1080\/09273948.2024.2323671","volume":"32","author":"P Dutta Majumder","year":"2024","unstructured":"Dutta Majumder P, Abraham S, Sudharshan S, Janarthanan M, Ramanan AV. Tofacitinib for refractory uveitis and scleritis in children: a case series. Ocul Immunol Inflamm. 2024;32(9):2092\u20135.","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03669-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:04:11Z","timestamp":1761905051000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03669-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3669"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03669-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6827548\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study is based on clinical data of JIA patients collected from patient records and from Finnish Rheumatology Quality Register. Therefore, according to Finnish legislation, there was no need of approval by an ethical committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}